Cargando…

Digital messaging to support control for type 2 diabetes (StAR2D): a multicentre randomised controlled trial

BACKGROUND: Failure to take medicines for diabetes as prescribed contributes to poor outcomes from the condition. Mobile phones are ubiquitous and short message service (SMS) texts have shown promise as a low-cost intervention. We tested the effectiveness of SMS-text messaging in improving outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales: Farmer, A., Bobrow, K., Leon, N., Williams, N., Phiri, E., Namadingo, H., Cooper, S., Prince, J., Crampin, A., Besada, D., Daviaud, E., Yu, L-M, N’goma, J., Springer, D., Pauly, B., Tarassenko, L., Norris, S., Nyirenda, M., Levitt, N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529732/
https://www.ncbi.nlm.nih.gov/pubmed/34674688
http://dx.doi.org/10.1186/s12889-021-11874-7
_version_ 1784586529120714752
author Farmer, A.
Bobrow, K.
Leon, N.
Williams, N.
Phiri, E.
Namadingo, H.
Cooper, S.
Prince, J.
Crampin, A.
Besada, D.
Daviaud, E.
Yu, L-M
N’goma, J.
Springer, D.
Pauly, B.
Tarassenko, L.
Norris, S.
Nyirenda, M.
Levitt, N.
author_facet Farmer, A.
Bobrow, K.
Leon, N.
Williams, N.
Phiri, E.
Namadingo, H.
Cooper, S.
Prince, J.
Crampin, A.
Besada, D.
Daviaud, E.
Yu, L-M
N’goma, J.
Springer, D.
Pauly, B.
Tarassenko, L.
Norris, S.
Nyirenda, M.
Levitt, N.
author_sort Farmer, A.
collection PubMed
description BACKGROUND: Failure to take medicines for diabetes as prescribed contributes to poor outcomes from the condition. Mobile phones are ubiquitous and short message service (SMS) texts have shown promise as a low-cost intervention. We tested the effectiveness of SMS-text messaging in improving outcomes in adults with type 2 diabetes. METHODS: StAR2D was a 12-month two-arm randomised trial of SMS-text messaging and usual care in Cape Town, South Africa and Lilongwe, Malawi. Messages used behaviour change theory and were developed with patients and staff. The intervention group received four messages each week. The primary outcome was change in HbA1c. Secondary outcomes were the proportion of patients who collected > 80% medication and changes in systolic blood pressure, lipids, cardiovascular risk, and the proportion of the participants reaching treatment goals. RESULTS: The trial took place between 1 October, 2016 and 1 October 2018, 1186 participants were randomised to intervention (593) and control (593) groups. 91% of participants completed follow-up. There was a reduction in HbA1c (DCCT) in both groups but not in mean change (95% CI) between groups (− 0.08% (− 0.31 to 0.16) (IFCC − 0.82 mmol/mol (− 3.44 to 1.79). There was a small but not significant increase in the proportions of participants likely to have collected 80% or more of medication (Relative risk 1.11 (0.84 to 1.47; P = 0.47). There was a significant difference between groups in change in systolic blood pressure from baseline of 3.46 mmHg (1.48 to 5.44, P = 0.001) in favour of the intervention group. The between group difference in change in 10-year risk of coronary heart disease was − 0.71% (− 1.46 to 0.04, P = 0.064). The proportion of participants meeting treatment goals in the intervention group was 36.0% and in the control group 26.8% (Relative risk 1.36 (1.13 to 1.63, P = 0.001). Participants reported many challenges to adherence despite finding messages acceptable and useful. CONCLUSIONS: Whilst SMS text messages do not lead to improved glycaemia in these low-resource settings there appeared to be an impact on blood pressure and achievement of treatment goals but the mechanisms for this are unclear. Text messages alone, may be unsuccessful unless accompanied by health system strengthening and other forms of self-management support for type 2 diabetes. TRIAL REGISTRATION: Trial registration: ISRCTN, ISRCTN70768808. Registered 1 July 2015, http://www.isrctn.com/I ISRCTN70768808. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12889-021-11874-7.
format Online
Article
Text
id pubmed-8529732
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85297322021-10-25 Digital messaging to support control for type 2 diabetes (StAR2D): a multicentre randomised controlled trial Farmer, A. Bobrow, K. Leon, N. Williams, N. Phiri, E. Namadingo, H. Cooper, S. Prince, J. Crampin, A. Besada, D. Daviaud, E. Yu, L-M N’goma, J. Springer, D. Pauly, B. Tarassenko, L. Norris, S. Nyirenda, M. Levitt, N. BMC Public Health Research Article BACKGROUND: Failure to take medicines for diabetes as prescribed contributes to poor outcomes from the condition. Mobile phones are ubiquitous and short message service (SMS) texts have shown promise as a low-cost intervention. We tested the effectiveness of SMS-text messaging in improving outcomes in adults with type 2 diabetes. METHODS: StAR2D was a 12-month two-arm randomised trial of SMS-text messaging and usual care in Cape Town, South Africa and Lilongwe, Malawi. Messages used behaviour change theory and were developed with patients and staff. The intervention group received four messages each week. The primary outcome was change in HbA1c. Secondary outcomes were the proportion of patients who collected > 80% medication and changes in systolic blood pressure, lipids, cardiovascular risk, and the proportion of the participants reaching treatment goals. RESULTS: The trial took place between 1 October, 2016 and 1 October 2018, 1186 participants were randomised to intervention (593) and control (593) groups. 91% of participants completed follow-up. There was a reduction in HbA1c (DCCT) in both groups but not in mean change (95% CI) between groups (− 0.08% (− 0.31 to 0.16) (IFCC − 0.82 mmol/mol (− 3.44 to 1.79). There was a small but not significant increase in the proportions of participants likely to have collected 80% or more of medication (Relative risk 1.11 (0.84 to 1.47; P = 0.47). There was a significant difference between groups in change in systolic blood pressure from baseline of 3.46 mmHg (1.48 to 5.44, P = 0.001) in favour of the intervention group. The between group difference in change in 10-year risk of coronary heart disease was − 0.71% (− 1.46 to 0.04, P = 0.064). The proportion of participants meeting treatment goals in the intervention group was 36.0% and in the control group 26.8% (Relative risk 1.36 (1.13 to 1.63, P = 0.001). Participants reported many challenges to adherence despite finding messages acceptable and useful. CONCLUSIONS: Whilst SMS text messages do not lead to improved glycaemia in these low-resource settings there appeared to be an impact on blood pressure and achievement of treatment goals but the mechanisms for this are unclear. Text messages alone, may be unsuccessful unless accompanied by health system strengthening and other forms of self-management support for type 2 diabetes. TRIAL REGISTRATION: Trial registration: ISRCTN, ISRCTN70768808. Registered 1 July 2015, http://www.isrctn.com/I ISRCTN70768808. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12889-021-11874-7. BioMed Central 2021-10-21 /pmc/articles/PMC8529732/ /pubmed/34674688 http://dx.doi.org/10.1186/s12889-021-11874-7 Text en © The Author(s) 2021, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Farmer, A.
Bobrow, K.
Leon, N.
Williams, N.
Phiri, E.
Namadingo, H.
Cooper, S.
Prince, J.
Crampin, A.
Besada, D.
Daviaud, E.
Yu, L-M
N’goma, J.
Springer, D.
Pauly, B.
Tarassenko, L.
Norris, S.
Nyirenda, M.
Levitt, N.
Digital messaging to support control for type 2 diabetes (StAR2D): a multicentre randomised controlled trial
title Digital messaging to support control for type 2 diabetes (StAR2D): a multicentre randomised controlled trial
title_full Digital messaging to support control for type 2 diabetes (StAR2D): a multicentre randomised controlled trial
title_fullStr Digital messaging to support control for type 2 diabetes (StAR2D): a multicentre randomised controlled trial
title_full_unstemmed Digital messaging to support control for type 2 diabetes (StAR2D): a multicentre randomised controlled trial
title_short Digital messaging to support control for type 2 diabetes (StAR2D): a multicentre randomised controlled trial
title_sort digital messaging to support control for type 2 diabetes (star2d): a multicentre randomised controlled trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529732/
https://www.ncbi.nlm.nih.gov/pubmed/34674688
http://dx.doi.org/10.1186/s12889-021-11874-7
work_keys_str_mv AT farmera digitalmessagingtosupportcontrolfortype2diabetesstar2damulticentrerandomisedcontrolledtrial
AT bobrowk digitalmessagingtosupportcontrolfortype2diabetesstar2damulticentrerandomisedcontrolledtrial
AT leonn digitalmessagingtosupportcontrolfortype2diabetesstar2damulticentrerandomisedcontrolledtrial
AT williamsn digitalmessagingtosupportcontrolfortype2diabetesstar2damulticentrerandomisedcontrolledtrial
AT phirie digitalmessagingtosupportcontrolfortype2diabetesstar2damulticentrerandomisedcontrolledtrial
AT namadingoh digitalmessagingtosupportcontrolfortype2diabetesstar2damulticentrerandomisedcontrolledtrial
AT coopers digitalmessagingtosupportcontrolfortype2diabetesstar2damulticentrerandomisedcontrolledtrial
AT princej digitalmessagingtosupportcontrolfortype2diabetesstar2damulticentrerandomisedcontrolledtrial
AT crampina digitalmessagingtosupportcontrolfortype2diabetesstar2damulticentrerandomisedcontrolledtrial
AT besadad digitalmessagingtosupportcontrolfortype2diabetesstar2damulticentrerandomisedcontrolledtrial
AT daviaude digitalmessagingtosupportcontrolfortype2diabetesstar2damulticentrerandomisedcontrolledtrial
AT yulm digitalmessagingtosupportcontrolfortype2diabetesstar2damulticentrerandomisedcontrolledtrial
AT ngomaj digitalmessagingtosupportcontrolfortype2diabetesstar2damulticentrerandomisedcontrolledtrial
AT springerd digitalmessagingtosupportcontrolfortype2diabetesstar2damulticentrerandomisedcontrolledtrial
AT paulyb digitalmessagingtosupportcontrolfortype2diabetesstar2damulticentrerandomisedcontrolledtrial
AT tarassenkol digitalmessagingtosupportcontrolfortype2diabetesstar2damulticentrerandomisedcontrolledtrial
AT norriss digitalmessagingtosupportcontrolfortype2diabetesstar2damulticentrerandomisedcontrolledtrial
AT nyirendam digitalmessagingtosupportcontrolfortype2diabetesstar2damulticentrerandomisedcontrolledtrial
AT levittn digitalmessagingtosupportcontrolfortype2diabetesstar2damulticentrerandomisedcontrolledtrial